Who is Merck/Sanofi Pasteur (MSP)?

Sanofi Pasteur MSD is a joint venture owned on a 50/50 basis by Sanofi Pasteur (the vaccine division of Sanofi) and Merck (known as MSD outside the United States and Canada). It was created in 1994 to develop and commercialize vaccines originating from both companies’ pipelines to improve and promote public health in 19 European countries. Over the past twenty years, Sanofi Pasteur MSD has launched numerous innovative vaccines originating from Sanofi Pasteur and MSD’s development pipelines, addressing key unmet medical needs and helping to protect millions of lives.

What is Vaxelis^TM Vaccine?

Vaxelis™ the much anticipated hexavalent vaccine developed collaboratively between Merck & Sanofi Pasteur is finally available through MPPG!

Vaxelis^TM is a hexavalent combination vaccine approved to prevent diphtheria, tetanus, pertussis, polio, Haemophilus influenzae type b, and hepatitis B.

When Was Vaxelis^TM Approved?

Approved by the FDA in 2018 and given the recommendation by the ACIP, Vaxelis™ will be an important leap forward in reducing the number of injections required for infant immunization.

Preferred Vaxelis^TM Pricing Now Available Through MPPG

The Vaxelis™ pricing program is a separate and new contract from other Sanofi Pasteur vaccines. For member practices who are interested in qualifying for the performance pricing, there is a marketshare component.  For details please reach out to us at (818) 332-7057 or by e-mail at ten.gppm@ofni.

MPPG Members may participate in the Vaxelis™ performance pricing program by completing the performance pricing form.

More details about Vaxelis™ may be found at website www.vaxelis.com

Who Makes Vaxelis^TM?

Vaxelis^TM is produced by Sanofi Pasteur MSD. The combined expertise resulting from Sanofi Pasteur and Merck’s research to focus on the development of new vaccines in Europe in order to produce the most effective, most acceptable and better tolerated vaccines. For more information visit: http://www.spmsd.com

What Does Vaxelis^TM Replace?

While two pentavalent vaccines, Pentacel® and Pediarix®, have been common options for reducing the number of shots in the infant vaccination series, Vaxelis^TM represents the first six-component version.

Can Vaxelis^TM be Used For Catch Up?

Yes, Vaxelis^TM can be used for older children behind on their immunization schedule. The vaccine may be used for children younger than age 5 requiring a catch-up primary series, using appropriate minimum intervals. It is not approved as the booster dose of DTaP [dose 4 or 5] or IPV [dose 4] or Hib [dose 4]. If Vaxelis^TM is inadvertently given as a booster dose, it may count as valid and does not need to be repeated.

Is Vaxelis^TM Interchangeable? (Vaxelis^TM With Other Vaccines)

Vaxelis^TM can be administered at the same visit with other vaccines, but in separate syringes. Specifically, it should not be mixed with or used to reconstitute any other vaccine. Discard unused portions. Vaxelis^TM is a suspension for injection available in 0.5 mL single-dose vials and prefilled syringes.

Can Vaxelis^TM be Given After Pentacel®? (Is Vaxelis^TM Interchangeable With Pentacel®?)

Vaxelis^TM may be used to complete the first 3 doses of the 5-dose DTaP series in infants and children who have received 1 or 2 doses of Pentacel® or Daptacel® and are also scheduled to receive the other antigens in Vaxelis^TM.